The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC

BACKGROUND: Activation of the oncogene YAP has been shown to be related to lung cancer progression and associates with poor prognosis and metastasis. Metformin is a drug commonly used in the treatment of diabetes and with anticancer activity. However, the mechanism through which metformin inhibits t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EBioMedicine
Glavni autori: Jin, Dan, Guo, Jiwei, Wang, Deqiang, Wu, Yan, Wang, Xiaohong, Gao, Yong, Shao, Cuijie, Xu, Xin, Tan, Shuying
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2018
Teme:
Research paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6284514/
https://ncbi.nlm.nih.gov/pubmed/30389502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.10.044
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items